This project is a drug discovery program aimed at finding new chemical entities capable of inhibiting the immunosuppression mediated by indoleamine 2,3-dioxygenase (IDO) expression in tumors. The project also encompasses a phase I/II clinical trial with a first-generation IDO inhibitor, and a diagnostic application leading to the development of new diagnostic test for detecting IDO-positive cancers.
|Effective start/end date||1/04/08 → 31/03/12|
- molecular design
- medicinal chemistry